Rabizadeh, Shahrooz,Niazi, Kayvan,Soon-Shiong, Patrick
申请号：
AU2018219862
公开号：
AU2018219862A1
申请日:
2018.02.08
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.
